Skip to content
value.today

Cronos Group Inc: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Pharmaceutical: $224 M to $982 M, median $507 MPrice to bookPrice to book of Pharmaceutical: $2.3 B to $9.1 B, median $4.4 B$0 M$2.5 B$4.9 B$7.4 B$9.8 BMarket value $1.2 B

Your own DCF model

A full discounted-cash-flow model of Cronos Group Inc, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Cronos Group Inc's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Cronos Group IncApplied toValue (25th to 75th)Companies
Price to sales1.5× / 3.5× / 6.7×5.9×revenue $147 M$224 M to $982 M68
Price to book2.1× / 4.1× / 8.3×1.1×book equity $1.1 B$2.3 B to $9.1 B62

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Cronos Group Inc's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

17.4×

Now close to its median of 17.4×; range 14.8× to 61.5× over 14 months.

0×15×31×46×62×2026P/E 17×Median 17×

Price to sales

6.8×

Now below its median of 7.0×; range 5.8× to 214.2× over 30 months.

0×54×107×161×214×2020202120222023202420252026Price to sales 7×Median 7×

Price to book

1.1×

Now above its median of 0.9×, in the top quarter of its range; range 0.6× to 17.5× over 30 months.

0×4×9×13×17×2020202120222023202420252026Price to book 1×Median 1×

as of Oct 31, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 31, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$147 M$-9 M$26 M$26 M$0 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$118 M$41 M$19 M$12 M$6 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$87 M$-74 M$-43 M$3 M$-45 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$87 M$-169 M$-89 M$3 M$-92 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$65 M$-396 M$-154 M$11 M$-165 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$47 M$-73 M$-145 M$31 M$-176 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $1.2 B on Oct 31, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.